Previous close | 92.92 |
Open | 93.96 |
Bid | 90.95 x 0 |
Ask | 92.81 x 0 |
Day's range | 91.35 - 94.57 |
52-week range | 80.62 - 104.70 |
Volume | |
Avg. volume | 1,554,105 |
Market cap | 121.19B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 13.41 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.56 (3.60%) |
Ex-dividend date | 30 May 2023 |
1y target est | N/A |
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a p
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. Th
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa